CPRX Form 4 shows new options and RSU grants to board chair

Rhea-AI Filing Summary

Catalyst Pharmaceuticals, Inc. (CPRX) reported an insider equity award for its Chairman of the Board and Director, Patrick J. McEnany. On 11/20/2025, he received options to purchase 34,921 shares of common stock at an exercise price of $22.77 per share, along with 10,540 restricted stock units (RSUs). The options and RSUs generally vest in three equal annual installments on November 20 of 2026, 2027, and 2028.

On 11/21/2025, 1,775 RSUs were settled, and McEnany acquired 1,775 shares of common stock, increasing his directly held common stock to 4,283,477 shares. Following these transactions, he also beneficially owned 1,881,816 derivative securities, including options and RSUs that will deliver common shares as they vest and are settled.

Insider Trade Summary

1,775 shares exercised/converted

Mixed 4 txns

Insider MCENANY PATRICK J

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	1,775	$0.00	--
Exercise	Common Stock, par value $0.001 per share	1,775	$0.00	--
Grant/Award	Options to purchase common stock	34,921	$0.00	--
Grant/Award	Restricted Stock Units	10,540	$0.00	--

Holdings After Transaction: Restricted Stock Units — 1,881,816 shares (Direct); Common Stock, par value $0.001 per share — 4,283,477 shares (Direct); Options to purchase common stock — 1,873,051 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027 and 1/3rd on November 20, 2028. Shares of common stock will be delivered to the Reporting Person upon vesting. Derivative securities vest in equal tranches, 1/3rd on November 21, 2025, 1/3rd on November 21, 2026, and 1/3rd on November 21, 2027. Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on November 21, 2025.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MCENANY PATRICK J

(Last) (First) (Middle)

355 ALHAMBRA CIRCLE, SUITE 801

(Street)

CORAL GABLES FL 33134

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CATALYST PHARMACEUTICALS, INC. [ CPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Chairman of Board of Directors

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.001 per share	11/21/2025		M		1,775	A	(1)	4,283,477	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to purchase common stock	$22.77	11/20/2025		A		34,921		(2)	11/20/2032	Common Stock	34,921	$0	1,873,051	D
Restricted Stock Units	(3)	11/20/2025		A		10,540		(2)	(3)	Common Stock	10,540	$0	1,883,591	D
Restricted Stock Units	(3)	11/21/2025		M			1,775	(4)	(5)	Common Stock	1,775	$0	1,881,816	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.

2. Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027 and 1/3rd on November 20, 2028.

3. Shares of common stock will be delivered to the Reporting Person upon vesting.

4. Derivative securities vest in equal tranches, 1/3rd on November 21, 2025, 1/3rd on November 21, 2026, and 1/3rd on November 21, 2027.

5. Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on November 21, 2025.

	/s/ Patrick J. McEnany	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Catalyst Pharmaceuticals (CPRX) report in this Form 4 filing?

The filing reports equity awards and related transactions for Chairman and Director Patrick J. McEnany, including new stock options, RSUs, and RSU settlement into common shares.

How many stock options did the CPRX chairman receive and at what price?

He received options to purchase 34,921 shares of Catalyst Pharmaceuticals common stock at an exercise price of $22.77 per share.

How many restricted stock units (RSUs) were granted to the CPRX reporting person?

On 11/20/2025, the reporting person was granted 10,540 restricted stock units (RSUs) that each represent a right to receive one share of common stock upon vesting.

What is the vesting schedule for the new Catalyst Pharmaceuticals options and RSUs?

The derivative securities vest in three equal tranches: 1/3 on November 20, 2026, 1/3 on November 20, 2027, and 1/3 on November 20, 2028, with related delivery of common shares upon vesting.

How many CPRX common shares did the insider acquire from RSU settlement?

On 11/21/2025, 1,775 shares of common stock were delivered to the reporting person upon vesting and settlement of RSUs.

What is the reporting person’s CPRX common stock ownership after these transactions?

After the reported transactions, the reporting person beneficially owned 4,283,477 shares of Catalyst Pharmaceuticals common stock directly.

How many derivative securities does the CPRX insider hold after the transactions?

Following the transactions, the reporting person beneficially owned 1,881,816 derivative securities, including stock options and restricted stock units tied to CPRX common stock.